Nordea Investment Management AB Sells 273,268 Shares of Amgen Inc. $AMGN

Key Points

• Nordea Investment Management AB trimmed its Amgen stake by 9.5%, selling 273,268 shares in Q4 and now holds 2,601,135 shares (about 0.48% of Amgen and 0.7% of Nordea’s portfolio, its 26th largest position).
• Amgen beat quarterly estimates, reporting $5.29 EPS vs. $4.76 expected and $9.87B revenue vs. $9.46B, and set FY2026 guidance of 21.600–23.000 EPS.
• The company declared a quarterly dividend of $2.52 (annualized $10.08) with a yield of 2.9%; ex-dividend date is May 15 and it will be paid June 5.

Nordea Investment Management AB trimmed its position in Amgen Inc. (NASDAQ:AMGN - Free Report) by 9.5% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 2,601,135 shares of the medical research company's stock after selling 273,268 shares during the period. Amgen comprises 0.7% of Nordea Investment Management AB's investment portfolio, making the stock its 26th biggest position. Nordea Investment Management AB owned approximately 0.48% of Amgen worth $851,924,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. West Family Investments Inc. boosted its position in Amgen by 1.1% during the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company's stock valued at $779,000 after buying an additional 30 shares during the period. Viawealth LLC increased its holdings in shares of Amgen by 0.4% in the third quarter. Viawealth LLC now owns 7,168 shares of the medical research company's stock worth $2,023,000 after buying an additional 30 shares during the period. LOM Asset Management Ltd increased its holdings in shares of Amgen by 1.2% in the third quarter. LOM Asset Management Ltd now owns 2,554 shares of the medical research company's stock worth $721,000 after buying an additional 30 shares during the period. Sittner & Nelson LLC lifted its stake in shares of Amgen by 0.4% in the 3rd quarter. Sittner & Nelson LLC now owns 7,276 shares of the medical research company's stock valued at $2,053,000 after acquiring an additional 30 shares during the last quarter. Finally, TAGStone Capital Inc. boosted its holdings in Amgen by 0.8% during the 3rd quarter. TAGStone Capital Inc. now owns 4,101 shares of the medical research company's stock valued at $1,157,000 after acquiring an additional 32 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Down 0.6%

Shares of NASDAQ:AMGN opened at $347.80 on Friday. The stock's 50-day moving average is $360.29 and its 200 day moving average is $327.80. The company has a market cap of $187.49 billion, a PE ratio of 24.44, a P/E/G ratio of 3.45 and a beta of 0.45. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $391.29.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping the consensus estimate of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts' expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The business's revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen's dividend payout ratio (DPR) is presently 70.84%.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. UBS Group raised their price target on Amgen from $380.00 to $390.00 and gave the stock a "buy" rating in a research report on Monday, January 26th. BMO Capital Markets boosted their price objective on Amgen from $335.00 to $372.00 and gave the company an "outperform" rating in a research report on Wednesday, December 3rd. Truist Financial increased their price objective on Amgen from $318.00 to $319.00 and gave the company a "hold" rating in a research note on Thursday, January 8th. Mizuho lifted their target price on shares of Amgen from $280.00 to $295.00 and gave the stock an "outperform" rating in a research note on Tuesday, February 10th. Finally, Piper Sandler upped their price target on shares of Amgen from $381.00 to $432.00 and gave the company an "overweight" rating in a report on Wednesday, February 18th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, Amgen has a consensus rating of "Hold" and a consensus target price of $354.60.

About Amgen

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.